Kaminski Michael M, Tosic Jelena, Pichler Roman, Arnold Sebastian J, Lienkamp Soeren S
Department of Medicine, Renal Division, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Albertstrasse 25, 79104, Freiburg, Germany.
Cell Tissue Res. 2017 Jul;369(1):185-197. doi: 10.1007/s00441-017-2629-5. Epub 2017 May 30.
Growing knowledge of how cell identity is determined at the molecular level has enabled the generation of diverse tissue types, including renal cells from pluripotent or somatic cells. Recently, several in vitro protocols involving either directed differentiation or transcription-factor-based reprogramming to kidney cells have been established. Embryonic stem cells or induced pluripotent stem cells can be guided towards a kidney fate by exposing them to combinations of growth factors or small molecules. Here, renal development is recapitulated in vitro resulting in kidney cells or organoids that show striking similarities to mammalian embryonic nephrons. In addition, culture conditions are also defined that allow the expansion of renal progenitor cells in vitro. Another route towards the generation of kidney cells is direct reprogramming. Key transcription factors are used to directly impose renal cell identity on somatic cells, thus circumventing the pluripotent stage. This complementary approach to stem-cell-based differentiation has been demonstrated to generate renal tubule cells and nephron progenitors. In-vitro-generated renal cells offer new opportunities for modelling inherited and acquired renal diseases on a patient-specific genetic background. These cells represent a potential source for developing novel models for kidney diseases, drug screening and nephrotoxicity testing and might represent the first steps towards kidney cell replacement therapies. In this review, we summarize current approaches for the generation of renal cells in vitro and discuss the advantages of each approach and their potential applications.
在分子水平上对细胞身份如何确定的认识不断深入,使得人们能够生成多种组织类型,包括由多能细胞或体细胞生成肾细胞。最近,已经建立了几种涉及定向分化或基于转录因子重编程为肾细胞的体外方案。胚胎干细胞或诱导多能干细胞可以通过使其暴露于生长因子或小分子的组合而被引导走向肾细胞命运。在此,肾发育过程在体外得以重现,从而产生与哺乳动物胚胎肾单位具有显著相似性的肾细胞或类器官。此外,还确定了允许肾祖细胞在体外扩增的培养条件。生成肾细胞的另一条途径是直接重编程。关键转录因子被用于直接赋予体细胞肾细胞身份,从而绕过多能阶段。这种基于干细胞分化的互补方法已被证明可产生肾小管细胞和肾单位祖细胞。体外生成的肾细胞为在患者特异性遗传背景下模拟遗传性和获得性肾病提供了新机会。这些细胞代表了开发肾病新模型、药物筛选和肾毒性测试的潜在来源,并且可能代表了肾细胞替代疗法的第一步。在本综述中,我们总结了当前体外生成肾细胞的方法,并讨论了每种方法的优点及其潜在应用。